New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
12:42 EDTITMNInterMune receives FDA Breakthrough Therapy Designation for pirfenidone
InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.
News For ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:11 EDTITMNRoche sees completing InterMune acquisition later today
Subscribe for More Information
September 22, 2014
13:53 EDTITMNRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
September 20, 2014
15:43 EDTITMNInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use